Shp099

Manufactured by Novartis

Sourced in Switzerland

SHP099 is a specialized lab equipment product manufactured by Novartis. It is designed to perform specific functions within a laboratory setting. The core function of SHP099 is to [DESCRIPTION NOT AVAILABLE].

Automatically generated - may contain errors

Lab products found in correlation

Epidermal growth factor (egf), by R&D Systems (1 mentions) Kx2 391, by Selleck Chemicals (1 mentions) Calf intestinal alkaline phosphatase, by New England Biolabs (1 mentions) Pdgf bb, by R&D Systems (1 mentions) Puromycin, by Thermo Fisher Scientific (1 mentions) Doxycycline, by Merck Group (1 mentions) 4 oht, by Merck Group (1 mentions) Hygromycin stock solution, by Thermo Fisher Scientific (1 mentions) Erlotinib, by MedChemExpress (1 mentions) Mek162, by Novartis (1 mentions) Sunitinib, by Pfizer (1 mentions) Lipopolysaccharide lps, by Merck Group (1 mentions) Tween 80, by Thermo Fisher Scientific (1 mentions) Methylcellulose, by Merck Group (1 mentions) Cremophor, by Merck Group (1 mentions)

5 protocols using shp099

Compound 11a-1: Structure-Guided Synthesis

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Compound 11a-1, 6-Hydroxy-3-iodo-1-methyl-2-(3-(2-oxo-2-((4-(thiophen-3-yl)-phenyl)amino)acetamido)phenyl)-1H-indole-5-carboxylic acid was developed and synthesized using a structure-guided and fragment-based library approach^{14 (link)}. SHP099 was obtained from Novartis. KX2-391 was obtained from Selleck Chemicals. Calf intestinal alkaline phosphatase was obtained from New England Biolabs. EGF and PDGF-BB were obtained from R&D Systems.

Kano Y., Gebregiworgis T., Marshall C.B., Radulovich N., Poon B.P., St-Germain J., Cook J.D., Valencia-Sama I., Grant B.M., Herrera S.G., Miao J., Raught B., Irwin M.S., Lee J.E., Yeh J.J., Zhang Z.Y., Tsao M.S., Ikura M, & Ohh M. (2019). Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation. Nature Communications, 10, 224.

+ Open protocol

+ Expand

Sourcing and Preparing Experimental Reagents

Check if the same lab product or an alternative is used in the 5 most similar protocols

erlotinib was obtained from MedChem Express. osimertinib was obtained from SelleckChem Express. SHP099 was provided by Novartis. Doxycycline and 4-OHT were from Sigma Aldrich. Puromycin and hygromycin stock solution were from Invitrogen. Drugs were dissolved in DMSO to yield 10mM stock and store at −20°C.

Su W., Mukherjee R., Yaeger R., Son J., Xu J., Na N., Timaul N.M., Hechtman J., Paroder V., Lin M., Mattar M., Qiu J., Chang Q., Zhao H., Zhang J., Little M., Adachi Y., Han S.W., Taylor B.S., Ebi H., Abdel-Wahab O., de Stanchina E., Rudin C.M., Jänne P.A., McCormick F., Yao Z, & Rosen N. (2022). ARAF protein kinase activates RAS by antagonizing its binding to the RASGAP NF1. Molecular cell, 82(13), 2443-2457.e7.

+ Open protocol

+ Expand

Preparation of SHP099 and MEK162

Check if the same lab product or an alternative is used in the 5 most similar protocols

SHP099 and MEK162 were obtained from Novartis (Basel, Switzerland and Cambridge, USA). Compounds were prepared as 10 mM stock solutions in DMSO and stored protected from light at –20 °C.

Amante R.J., Auf der Maur P., Richina V., Sethi A., Iesmantavicius V., Bonenfant D., Aceto N, & Bentires-Alj M. (2022). Protein Tyrosine Phosphatase SHP2 Controls Interleukin-8 Expression in Breast Cancer Cells. Journal of Mammary Gland Biology and Neoplasia, 27(2), 145-153.

+ Open protocol

+ Expand

Oral Administration of Targeted Compounds

Check if the same lab product or an alternative is used in the 5 most similar protocols

CLR457 and SHP099 were obtained from Novartis (Basel, Switzerland and Cambridge, USA), and Sunitinib from Pfizer Inc (Sutent). Compounds were prepared as 10 mM stock solutions in DMSO and stored protected from light at –20 °C. CLR457 (20 mg/kg), SHP099 (100 mg/kg) and Sunitinib (60 mg/kg) were freshly formulated in methylcellulose / Tween-80 (0.5% / 0.5%) and administered to mice by oral gavage at 5 ml/kg.

Amante R.J., Jehanno C., De Silva D., Coissieux M.M., Ackerknecht M., Romanet V., Sethi A., Hamelin B., Preca B.T., Piscuoglio S., Ng C.K., Mohseni M, & Bentires-Alj M. (2023). PI3K inhibition circumvents resistance to SHP2 blockade in metastatic triple-negative breast cancer. Journal of Mammary Gland Biology and Neoplasia, 28(1), 13.

+ Open protocol

+ Expand

LPS-Induced Inflammation and Therapeutic Interventions

Cited 2 times

Check if the same lab product or an alternative is used in the 5 most similar protocols

Lipopolysaccharide (LPS) was purchased from Sigma (Cat # L8643) and dissolved in sterile phosphate-buffered saline (PBS) prior to being administered to mice (single dose; 0.8 mg/kg, i.p.). E3330, also called APX3330 was synthesized as described (Jiang et al., 2010 (link); Nyland et al., 2010 (link)). E3330 was dissolved in Cremophor: EtOH (1:1) (Cremophor was purchased from Sigma, Cat # C5135) for stock solution generation and diluted in PBS prior to use for pre-LPS treatment or post-LPS treatment (20 mg/kg, twice a day, i.p. for Figure S6A; 20 mg/kg, one dose per day, daily by gavage for experiments in Figure 6C, 6D, 6E and Figure S6C and S6D). SHP099 (provided by Novartis), was dissolved in 0.5% Methylcellulose (Sigma, Cat# M0262) and 0.1% Tween-80 (Fisher Scientific, Cat #BP338–500) and given to animals by gavage (daily, 50 mg/kg) for all the in vivo treatments. Male and female mice between 3–4 weeks as juvenile mice, or 8–16 weeks of age as adult mice, or 6~8 month of age as aged mice, were used for indicated experiments.

Cai Z., Kotzin J.J., Ramdas B., Chen S., Nelanuthala S., Palam L.R., Pandey R., Mali R.S., Liu Y., Kelley M.R., Sandusky G., Mohseni M., Williams A., Henao-Mejia J, & Kapur R. (2018). Inhibition of Inflammatory Signaling in Tet2 Mutant Preleukemic Cells Mitigates Stress Induced Abnormalities and Clonal Hematopoiesis. Cell stem cell, 23(6), 833-849.e5.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!